Check out Lialda for induction of remission in active mild to moderate UC and maintenance of UC remission. Read safety info including potential kidney. Shire US Manufacturing Inc.: LIALDA is indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis and for. Easy to read FDA package insert, drug facts, dosage and administration, and adverse effects for Lialda (mesalamine).
|Published (Last):||11 December 2011|
|PDF File Size:||11.71 Mb|
|ePub File Size:||7.83 Mb|
|Price:||Free* [*Free Regsitration Required]|
See Additional Important Safety Information. E-mail this page or Web site to a friend or loved one by filling out the form below.
All other intellectual property rights are reserved. Please see Full Prescribing Information for Lialda mesalamine. For the induction of remission in patients with active, mild to moderate ulcerative colitis UC and for the maintenance of remission of UC.
Ulcerative Colitis (UC) Treatment | Lialda® (mesalamine)
Click OK if you are a health care professional. Click “Cancel” to return or “OK” to continue. Kidney problems have been reported with medications that contain mesalamine, such as Lialda.
Talk to your doctor about why Lialda may be right for you. Liaalda is a prescription medication approved for the induction of remission in patients with active, mild to moderate ulcerative colitis UC and for the maintenance of remission of UC.
E-mail to a Friend
In clinical studies of Lialda, inflammation of the pancreas also occurred. This site is intended solely for US residents and is governed solely by US laws and government regulations. E—mail this list of questions for the doctor — to yourself, a friend or a loved one — by filling out the form below.
Tell your doctor if you: You are encouraged to report negative side effects of prescription drugs to the FDA. The information contained in this section of the site is intended for US health care professionals only.
See Full Important Safety Information. All fields are required. All content on this Web site, including text, images, graphics, sound files, and their arrangement, belongs to Shire and is protected by international copyright laws. Find information about UC.